Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Next Vial vs Obu Health

Next Vial
Graded #345

Lower grade

vs+0.6000000000000014
Obu Health
Graded #332

Higher grade

The verdict

Obu Health takes it — 59.9/100 to 59.3/100, but only just.

Obu Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons. Next Vial is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueObu Health +4
40
44
Dose & formulationObu Health +12
52
64
Clinical oversightObu Health +2
82
84
Labs & monitoringObu Health +1
52
53
FulfillmentNext Vial +12
86
74
Contract termsNext Vial +24
55
31
Next Vial · left barObu Health · right bar

The numbers

MetricNext VialObu Health
WeighScore59.3/10059.9/100
GradeCC
Scorecard rank#345#332
Semaglutide$250/mo (compounded)$190/mo (starting dose, plus a separate fee, compounded)
TirzepatideNot disclosed$239/mo (starting dose, plus a separate fee, compounded)
Coverage49 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Next Vial

Graded #345 · C

Strengths

  • LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
  • No membership fees — one all-in price covering consultation, medication, and shipping
  • Compounded semaglutide, tirzepatide, and microdose options available
  • Free rushed shipping; serves 49 states nationwide
  • Board-certified physician oversight with ongoing provider support

Where it loses points

  • Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
  • Compounded medications are not FDA-approved
  • Labs and nutritional coaching not disclosed
  • Microdose pricing not published on product page
  • Alaska not listed among served states
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard